香港股市 將收市,收市時間:21 分鐘

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
35.99-0.51 (-1.40%)
收市:04:00PM EST
35.87 -0.12 (-0.33%)
收市後: 08:00PM EST

Immunovant, Inc.

320 West 37th Street
6th Floor
New York, NY 10018
United States
(917) 580-3099
https://immunovant.com

版塊Healthcare
行業Biotechnology
全職員工164

高階主管

名稱頭銜支付行使價出生年份
Dr. Frank M. Torti M.B.A., M.D.Executive Chairperson of the Board92.5k1979
Dr. Peter Salzmann M.B.A., M.D.CEO & Director1.02M1968
Ms. Eva Renee Barnett M.B.A.Chief Financial Officer871.07k1980
Dr. William L. Macias M.D., Ph.D.Chief Medical Officer719.88k1958
Dr. Jay S. Stout Ph.D.Chief Technology Officer1963
Dr. Chau Cheng M.B.A., Ph.D.Vice President of Investor Relations
Mr. Mark S. LevineChief Legal Officer & Corporate Secretary1973
Ms. Lauren Schrier M.B.A.Vice President of Marketing
Ms. Christine BlodgettVice President of Human Resources
Dr. Julia G. Butchko Ph.D.Chief Development Officer531k1971
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

公司管治

截至 2024年2月1日 止,Immunovant, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中:6;董事會:10;股東權利:10;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。